Define the operating boundary
A useful definition names the triggering event, required inputs, governing source, accountable owner, decision or action, exception path, evidence retained, and downstream handoff. Buyers should adapt those elements to their own population, jurisdictions, policies, systems, and control model before writing requirements.
The most important distinction is between a label and an operational capability. A provider may document guided laboratory procedure and worksheet execution while depending on customer-supplied policy, licensed content, third-party data, integration partners, manual review, or services. The demonstration should expose those dependencies rather than hiding them behind a completed interface.
What a demonstration should prove
- Begin with representative source records and a named policy, standard, or controlled rule.
- Show the normal path, an ambiguous case, missing data, an exception, an override, and a material source change.
- Identify who can change rules, who can approve or reject, and how accountability is preserved.
- Trace every output back to inputs, versions, timestamps, user actions, and governing evidence.
- Export the resulting record and reconcile it with downstream systems and retained obligations.
Authority and operating context
21 CFR 211.194
The section specifies content for laboratory records, including samples, methods, test data, calculations, results, initials, dates, second-person review, and investigation references. It anchors a buyer's record model for sample identity, method control, raw data, calculation, result review, and traceable exceptions in relevant drug-manufacturing laboratories.
FDA Computer Software Assurance Guidance
The guidance describes a risk-based approach to establishing confidence in automation used for production or quality systems, including intended use, risk analysis, assurance activities, records, and appropriate testing. It gives laboratory and quality buyers a disciplined way to separate vendor evidence, configured intended use, process risk, assurance activity, unscripted testing, and retained objective evidence.
EU GMP Chapter 4
Chapter 4 places specifications, instructions, procedures, records, reports, controls, approval, availability, legibility, traceability, correction, retention, and hybrid-system relationships within the pharmaceutical quality system. Laboratory architecture should show which system owns each instruction, specification, raw record, result, review, approval, exception, and retained copy across electronic and paper processes.
ISO/IEC 17025:2017
ISO/IEC 17025 specifies requirements for laboratory competence, impartiality, and consistent operation across resources, processes, and management systems. A laboratory platform can support requests, methods, equipment, samples, technical records, results, reporting, nonconforming work, and improvement while competence remains an organizational and technical determination.
ISO 15189:2022
ISO 15189 specifies quality and competence requirements for medical laboratories, including governance, resources, pre-examination, examination, post-examination, information, risk, and improvement. Clinical laboratory systems should support patient and specimen identity, orders, methods, results, critical communication, quality, records, and interfaces while clinical competence and diagnostic validity remain outside software alone.
ISO 9001:2015
ISO 9001 specifies requirements for a quality management system covering context, leadership, planning, support, operation, performance evaluation, and improvement. Laboratory systems can support controlled operational records and evidence, but the quality system spans leadership, competence, risk, suppliers, process performance, nonconformity, and improvement.
Operating domains
Method, procedure, and laboratory execution control
The maintained relationship among approved methods, parameters, specifications, versioned instructions, execution steps, observations, calculations, deviations, and reviewer evidence.
Evidence and comparison limits
Official provider documentation can establish product positioning. Provider confirmation can clarify package or availability. Independent observation requires a disclosed scenario, environment, date, inputs, and reproducible result. None of those sources alone establishes buyer-specific legal, clinical, regulatory, quality, or operational fitness.
Buyer questions
- What exact outcome and evidence should guided laboratory procedure and worksheet execution produce?
- Which source, version, and customer facts govern the workflow?
- Which decisions remain human and who is accountable for them?
- What is native, configured, integrated, service-delivered, or planned?
- How does a changed source affect open and historical records?
Recent changes
EU GMP Annex 11 keeps vendor and system-owner responsibilities visible — Laboratory-system evidence is decision-useful only when the market label, authoritative record, configured workflow, scientific data, technical control, accountable reviewer, and unresolved boundary remain visible.
Allotrope separates scientific format, data model, and controlled terminology — Laboratory-system evidence is decision-useful only when the market label, authoritative record, configured workflow, scientific data, technical control, accountable reviewer, and unresolved boundary remain visible.
TetraScience's Tetra OS record clarifies the scientific-data platform boundary — Laboratory-system evidence is decision-useful only when the market label, authoritative record, configured workflow, scientific data, technical control, accountable reviewer, and unresolved boundary remain visible.